Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Abceutics Inc
Profile last edited on: 9/28/22      CAGE: 8PYU1      UEI: WN1QJMG5ZNC5

Business Identifier: Enabling better cancer treatments
Year Founded
2020
First Award
2021
Latest Award
2021
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

701 Ellicott Street
Buffalo, NY 14203
   (716) 531-6837
   abceutics.nguyen@gmail.com
   www.abceuticsinc.com/
Location: Single
Congr. District: 26
County: Erie

Public Profile

Working on the cutting-edge of biotechnology, the highly skilled and long-time experienced team assembled by Abceutics Inc are structured around offering solution to improve ADC technology. An area of primary focus of the very young firm is development of the first in a series of new drugs -- called payload-binding selectivity enhancers (PBSEs) -- that aim to improve the safety and efficacy of certain cancer drugs.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$168,038
Phase II Dollars
$0
Total Awarded
$168,038

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2021 1 NIH $168,038
Project Title: Lead Optimization and Evaluation of Anti-SN38 Payload Binding Selectivity Enhancers

Key People / Management

  Joseph Balthasar -- Co-founder and President

  Larry C Wienkers -- Co-founder and Chief Scientific Officer

Company News

There are no news available.